{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:44:15Z","timestamp":1778049855527,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["In Silico Pharmacol."],"DOI":"10.1007\/s40203-025-00393-7","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T04:38:32Z","timestamp":1752640712000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Oral absorption of semaglutide: pharmacokinetic modeling and molecular dynamics simulations"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6565-6779","authenticated-orcid":false,"given":"Palak Nitin","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3873-0899","authenticated-orcid":false,"given":"Ian S.","family":"Haworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"393_CR1","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s11154-022-09735-8","volume":"23","author":"VR Aroda","year":"2022","unstructured":"Aroda VR, Blonde L, Pratley RE (2022) A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Rev Endocr Metab Disord 23:979\u2013994. https:\/\/doi.org\/10.1007\/s11154-022-09735-8","journal-title":"Rev Endocr Metab Disord"},{"key":"393_CR2","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/cpdd.938","volume":"10","author":"TA Baekdal","year":"2021","unstructured":"Baekdal TA, Donsmark M, Hartoft-Nielsen ML, S\u00f8ndergaard FL, Connor A (2021) Relationship between oral semaglutide tablet erosion and pharmacokinetics: a pharmacoscintigraphic study. Clin Pharmacol Drug Dev 10:453\u2013462. https:\/\/doi.org\/10.1002\/cpdd.938","journal-title":"Clin Pharmacol Drug Dev"},{"key":"393_CR3","unstructured":"Bjerregaard Jensen S, Sauerberg P, Nielsen FS, Pedersen BL, Skibsted E (2018) Tablet formulation comprising semaglutide and a delivery agent. United States Patent US9993430B2"},{"key":"393_CR4","doi-asserted-by":"publisher","first-page":"7047","DOI":"10.1126\/scitranslmed.aar7047","volume":"10","author":"ST Buckley","year":"2018","unstructured":"Buckley ST, B\u00e6kdal TA, Vegge A, Maarbjerg SJ, Pyke C, Ahnfelt-R\u00f8nne J, Madsen KG, Sch\u00e9ele SG, Alanentalo T, Kirk RK, Pedersen BL, Skyggebjerg RB, Benie AJ, Strauss HM, Wahlund PO, Bjerregaard S, Farkas E, Fekete C, S\u00f8ndergaard FL, Borregaard J, Hartoft-Nielsen ML, Knudsen LB (2018) Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med 10:7047. https:\/\/doi.org\/10.1126\/scitranslmed.aar7047","journal-title":"Sci Transl Med"},{"key":"393_CR5","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s11095-022-03265-3","volume":"39","author":"H Chen","year":"2022","unstructured":"Chen H, Lu Y, Shi S, Zhang Q, Cao X, Sun L, An D, Zhang X, Kong X, Liu J (2022) Design and development of a new glucagon-like peptide-1 receptor agonist to obtain high oral bioavailability. Pharm Res 39:1891\u20131906. https:\/\/doi.org\/10.1007\/s11095-022-03265-3","journal-title":"Pharm Res"},{"key":"393_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/phar.70007","author":"L Hooper","year":"2025","unstructured":"Hooper L, Liu S, Pai MP (2025) GLP-1RA-induced delays in gastrointestinal motility: predicted effects on coadministered drug absorption by PBPK analysis. Pharmacotherapy. https:\/\/doi.org\/10.1002\/phar.70007","journal-title":"Pharmacotherapy"},{"key":"393_CR7","doi-asserted-by":"publisher","first-page":"170419","DOI":"10.1016\/j.peptides.2020.170419","volume":"134","author":"R Kamakura","year":"2020","unstructured":"Kamakura R, Raza GS, Prasannan A, Walkowiak J, Herzig KH (2020) Dipeptidyl peptidase-4 and GLP-1 interplay in STC-1 and GLUTag cell lines. Peptides 134:170419. https:\/\/doi.org\/10.1016\/j.peptides.2020.170419","journal-title":"Peptides"},{"key":"393_CR8","doi-asserted-by":"publisher","first-page":"9936","DOI":"10.3390\/ijms22189936","volume":"22","author":"HS Kim","year":"2021","unstructured":"Kim HS, Jung CH (2021) Oral semaglutide, the first ingestible glucagon-like peptide-1 receptor agonist: could it be a magic bullet for type 2 diabetes? Int J Mol Sci 22:9936. https:\/\/doi.org\/10.3390\/ijms22189936","journal-title":"Int J Mol Sci"},{"key":"393_CR9","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/jcc.23899","volume":"36","author":"E Krieger","year":"2015","unstructured":"Krieger E, Vriend G (2015) New ways to boost molecular dynamics simulations. J Comput Chem 36:996\u20131007. https:\/\/doi.org\/10.1002\/jcc.23899","journal-title":"J Comput Chem"},{"key":"393_CR10","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1111\/bcp.15816","volume":"89","author":"TR Machado","year":"2023","unstructured":"Machado TR, Honorio T, Souza Domingos TF, Candido de Paula DDS, Cabral LM, Rodrigues CR, Abrahim-Vieira BA, Teles de Souza AM (2023) Physiologically based pharmacokinetic modelling of semaglutide in children and adolescents with healthy and obese body weights. Br J Clin Pharmacol 89:3175\u20133194. https:\/\/doi.org\/10.1111\/bcp.15816","journal-title":"Br J Clin Pharmacol"},{"key":"393_CR11","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","volume":"11","author":"JA Maier","year":"2015","unstructured":"Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C (2015) ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput 11:3696\u20133713. https:\/\/doi.org\/10.1021\/acs.jctc.5b00255","journal-title":"J Chem Theory Comput"},{"key":"393_CR12","first-page":"1459","volume":"13","author":"M Manasa","year":"2022","unstructured":"Manasa M, Aanandhi MV (2022) Stability indicating RP-UPLC method development validation and dissolution testing of semaglutide. J Pharm Negat. Results 13:1459\u20131464","journal-title":"J Pharm Negat. Results"},{"key":"393_CR13","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Mol Metab 46:101102. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102","journal-title":"Mol Metab"},{"key":"393_CR14","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s40262-021-01025-x","volume":"60","author":"RV Overgaard","year":"2021","unstructured":"Overgaard RV, Navarria A, Ingwersen SH, B\u00e6kdal TA, Kildemoes RJ (2021) Clinical pharmacokinetics of oral semaglutide: analyses of data from clinical pharmacology trials. Clin Pharmacokinet 60:1335\u20131348. https:\/\/doi.org\/10.1007\/s40262-021-01025-x","journal-title":"Clin Pharmacokinet"},{"key":"393_CR15","doi-asserted-by":"publisher","first-page":"107019","DOI":"10.1016\/j.medcli.2025.107019","volume":"165","author":"MA P\u00e9rez-Velasco","year":"2025","unstructured":"P\u00e9rez-Velasco MA, Bernal-L\u00f3pez MR, Trenas A, Ricci M, L\u00f3pez-Carmona MD, Garc\u00eda de Lucas MD, G\u00f3mez-Huelgas R, P\u00e9rez-Belmonte LM (2025) Efficacy of once-weekly semaglutide in patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes. Med Clin (Barc) 165:107019","journal-title":"Med Clin (Barc)"},{"key":"393_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1021\/acs.bioconjchem.4c00484","volume":"36","author":"E P\u0159\u00e1da Brichtov\u00e1","year":"2025","unstructured":"P\u0159\u00e1da Brichtov\u00e1 E, Edu IA, Li X, Becher F, Gomes Dos Santos AL, Jackson SE (2025) Effect of lipidation on the structure, oligomerization, and aggregation of glucagon-like peptide 1. Bioconjug Chem 36:401\u2013414. https:\/\/doi.org\/10.1021\/acs.bioconjchem.4c00484","journal-title":"Bioconjug Chem"},{"key":"393_CR17","doi-asserted-by":"publisher","DOI":"10.26434\/chemrxiv-2025-n24f8","author":"ST Schneebeli","year":"2025","unstructured":"Schneebeli ST, Colston KJ, Faivre KT (2025) Permeation enhancer-induced membrane defects assist the oral absorption of peptide drugs. ChemRxiv. https:\/\/doi.org\/10.26434\/chemrxiv-2025-n24f8","journal-title":"ChemRxiv"},{"key":"393_CR18","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s12325-020-01548-y","volume":"38","author":"A Shi","year":"2021","unstructured":"Shi A, Xie P, Nielsen LL, Skj\u00f8th TV, He X, Haugaard SP (2021) Pharmacokinetics, safety and tolerability of once-weekly subcutaneous semaglutide in healthy Chinese subjects: a double-blind, phase 1, randomized controlled trial. Adv Ther 38:550\u2013561. https:\/\/doi.org\/10.1007\/s12325-020-01548-y","journal-title":"Adv Ther"},{"key":"393_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.2337\/cd22-0118","volume":"42","author":"C Solis-Herrera","year":"2024","unstructured":"Solis-Herrera C, Kane MP, Triplitt C (2024) Current understanding of sodium N-(8-[2-hydroxylbenzoyl] amino) caprylate (SNAC) as an absorption enhancer: the oral semaglutide experience. Clin Diabetes 42:74\u201386. https:\/\/doi.org\/10.2337\/cd22-0118","journal-title":"Clin Diabetes"},{"key":"393_CR20","doi-asserted-by":"publisher","first-page":"106838","DOI":"10.1016\/j.ejps.2024.106838","volume":"200","author":"Z Sun","year":"2024","unstructured":"Sun Z, Zhao N, Zhao X, Wang Z, Liu Z, Cui Y (2024) Application of physiologically based pharmacokinetic modeling of novel drugs approved by the U.S. food and drug administration. Eur J Pharm Sci 200:106838. https:\/\/doi.org\/10.1016\/j.ejps.2024.106838","journal-title":"Eur J Pharm Sci"},{"key":"393_CR21","doi-asserted-by":"publisher","first-page":"10122","DOI":"10.1039\/d0sm01011a","volume":"16","author":"M Venanzi","year":"2020","unstructured":"Venanzi M, Savioli M, Cimino R, Gatto E, Palleschi A, Ripani G, Cicero D, Placidi E, Orvieto F, Bianchi E (2020) A spectroscopic and molecular dynamics study on the aggregation process of a long-acting lipidated therapeutic peptide: the case of semaglutide. Soft Matter 16:10122\u201310131. https:\/\/doi.org\/10.1039\/d0sm01011a","journal-title":"Soft Matter"},{"key":"393_CR22","doi-asserted-by":"publisher","first-page":"109374","DOI":"10.1016\/j.celrep.2021.109374","volume":"36","author":"X Zhang","year":"2021","unstructured":"Zhang X, Belousoff MJ, Liang YL, Danev R, Sexton PM, Wootten D (2021) Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes. Cell Rep 36:109374. https:\/\/doi.org\/10.1016\/j.celrep.2021.109374","journal-title":"Cell Rep"},{"key":"393_CR23","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"18","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J (2024) Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther 18:234. https:\/\/doi.org\/10.1038\/s41392-024-01931-z","journal-title":"Signal Transduct Target Ther"}],"container-title":["In Silico Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40203-025-00393-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40203-025-00393-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40203-025-00393-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T11:53:56Z","timestamp":1757246036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40203-025-00393-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["393"],"URL":"https:\/\/doi.org\/10.1007\/s40203-025-00393-7","relation":{},"ISSN":["2193-9616"],"issn-type":[{"value":"2193-9616","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"6 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}